Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

PHASE1SuspendedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 2, 2021

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Acute LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells

"To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose.~Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants.~Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume."

Trial Locations (3)

30322

Children's Healthcare of Atlanta at Egleston, Atlanta

Emory University, Atlanta

Winship Cancer Institute of Emory University, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ossium Health, Inc.

INDUSTRY

lead

Edwin Horwitz

OTHER

NCT04328714 - Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease | Biotech Hunter | Biotech Hunter